Here's How To Lower Hematocrit While On TRT

High Hematocrit on TRT: The Side Effect You Cannot Afford to Ignore

If you are on testosterone replacement therapy and your doctor has not mentioned hematocrit, find a new doctor. That might sound harsh, but elevated hematocrit is arguably the most clinically significant side effect of TRT, and it is the one that can actually put you in the hospital if it goes unchecked. This video from Southwest Integrative Medicine provides a practical guide to understanding and managing hematocrit while on testosterone, and the information here could genuinely prevent a serious health event.

Hematocrit measures the percentage of your blood volume that is made up of red blood cells. Normal ranges are typically 38 to 50 percent for men, though the exact reference range varies slightly between labs. Testosterone stimulates your kidneys to produce more erythropoietin (EPO), which in turn tells your bone marrow to produce more red blood cells. More red blood cells means higher hematocrit. For many men on TRT, this is a predictable and manageable side effect. For some, it becomes a problem that needs aggressive attention.

Why Elevated Hematocrit Is Dangerous

When hematocrit climbs too high, your blood becomes thicker and more viscous. Think of the difference between water and honey flowing through a straw. Thicker blood moves more slowly, increases the workload on your heart, raises blood pressure, and creates conditions favorable for blood clot formation. The risk of stroke, deep vein thrombosis, pulmonary embolism, and heart attack all increase when hematocrit is chronically elevated.

The threshold where risk becomes significant is debated, but most providers consider hematocrit above 52 to 54 percent to be the action point. Some men on TRT will sit comfortably in the high-normal range and never have issues. Others will push past 54 percent within the first few months. Individual variation in this response is substantial and influenced by factors including genetics, hydration status, altitude, smoking, sleep apnea, and baseline hematocrit before starting TRT.

The insidious thing about elevated hematocrit is that it often produces no symptoms until it becomes dangerously high. Some men notice headaches, flushing, dizziness, or a sense of pressure in their head. Others feel completely fine with a hematocrit of 56 percent. This is why regular bloodwork is not optional. You cannot feel your way through this one.

Strategy 1: Optimize Your TRT Protocol

The first line of defense against elevated hematocrit is protocol optimization. Injection frequency is the single biggest modifiable factor. Testosterone peaks stimulate erythropoiesis more aggressively than stable levels. Men who inject every two weeks experience large peaks that drive disproportionate red blood cell production. Switching to twice-weekly or every-other-day injections flattens these peaks and often brings hematocrit down by 2 to 4 percentage points without changing the total weekly dose.

Dose reduction is the second lever. If your testosterone levels are above the normal reference range, bringing them into the upper-normal zone (600 to 900 ng/dL for most men) can reduce hematocrit while still providing symptom relief. The goal of TRT is replacement, not maximization, and keeping doses in the therapeutic range naturally limits the erythropoietic stimulus.

Switching delivery methods can also help. Topical testosterone (gels, creams, patches) generally produces lower and more stable testosterone levels than injections, resulting in less hematocrit elevation. For men who struggle with chronically elevated hematocrit on injectable testosterone, a switch to topical delivery is worth considering.

Strategy 2: Therapeutic Phlebotomy and Blood Donation

Phlebotomy, the removal of blood, is the most direct way to lower hematocrit. When you remove a unit of blood, your body replaces the plasma volume within 24 to 48 hours but takes several weeks to fully replace the red blood cells. The net result is a temporary but meaningful reduction in hematocrit.

Blood donation is the most accessible form of phlebotomy for most men. Donating a unit of whole blood every 8 to 12 weeks can keep hematocrit in a safe range for many men on TRT. However, blood banks will defer you if your hematocrit is above their cutoff (usually 54 to 56 percent), which creates a frustrating catch-22 where the men who need phlebotomy most may not qualify for donation.

In those cases, therapeutic phlebotomy ordered by your doctor is the alternative. Your provider writes a prescription for phlebotomy, and it is performed at a lab or infusion center. The removed blood is typically discarded rather than donated. While this solves the logistical problem, it can be harder to arrange and may not be covered by insurance.

Strategy 3: Lifestyle and Supplemental Approaches

Hydration has a real impact on hematocrit. Dehydration concentrates blood and artificially elevates hematocrit readings. Staying consistently well-hydrated can keep your numbers a few points lower than they would otherwise be. This is not a solution for genuinely elevated hematocrit, but it prevents dehydration from compounding the problem.

Grapefruit and grapefruit juice contain naringenin, a flavonoid that has been shown in some studies to mildly inhibit erythropoiesis. The clinical significance of this effect is modest, but some men incorporate it as an additional measure. Fish oil, which has mild blood-thinning properties, is another supplement that some providers recommend for men with borderline hematocrit elevation.

Sleep apnea screening and treatment deserves special mention. Untreated sleep apnea causes chronic intermittent hypoxia, which stimulates EPO production independently of testosterone. Treating sleep apnea can reduce hematocrit by addressing this additional driver of red blood cell production.

Monitoring Schedule and Action Thresholds

At minimum, CBC with hematocrit should be checked at baseline before starting TRT, at 6 to 8 weeks after starting or changing dose, at 3 months, 6 months, and then every 6 to 12 months on a stable protocol. If hematocrit exceeds 52 percent, increase monitoring frequency and consider protocol adjustments. If it exceeds 54 percent, take active steps including dose reduction, frequency increase, or phlebotomy. If it exceeds 56 percent, phlebotomy should be performed urgently and the TRT protocol needs significant modification.

Who Should Watch This

Every man on TRT should watch this video. Hematocrit management is not optional, and understanding the strategies for controlling it gives you the ability to have informed conversations with your provider. It is especially important for men who have been on TRT for a while without recent bloodwork, men who inject infrequently, men who live at higher altitudes, smokers, and men with sleep apnea. If your hematocrit has been creeping up and your provider's only suggestion is to stop TRT, this video shows you the options that should be explored before abandoning treatment.

The Long-Term Hematocrit Management Mindset

Hematocrit management on TRT is not a one-time fix. It is an ongoing process that requires regular attention and adjustment. Your hematocrit can change over time due to aging, changes in body composition, altitude changes, new medications, changes in hydration habits, and evolution of your sleep apnea status. A hematocrit that was well-controlled at 49 percent for two years can creep up to 53 percent if you gain weight, start sleeping poorly, or move to a higher altitude.

Building hematocrit management into your routine rather than treating it as a crisis to be dealt with when it spikes is the most effective approach. Schedule regular blood donations if your levels run in the high-normal range. Stay consistently hydrated rather than binge-drinking water before lab draws. Maintain your exercise routine, as cardiovascular fitness helps regulate red blood cell production. Address any sleep apnea symptoms promptly. And communicate proactively with your provider about hematocrit trends rather than waiting until it becomes an urgent problem.

The men who manage hematocrit successfully over the long term are the ones who treat it as a normal part of TRT maintenance rather than a scary side effect. It is no different from monitoring blood pressure on blood pressure medication or checking blood sugar on diabetes medication. It is a number you track, a number you act on when it moves out of range, and a number that should not cause anxiety when it is being managed competently. This video gives you the knowledge to be an active participant in that management process rather than a passive bystander wondering why your face looks red after your injection.

If there is one message to take away from this video, it is that hematocrit is the side effect you cannot afford to ignore, but also the one that you do not need to fear if you are proactive about managing it. The tools are available. The monitoring is straightforward. And the consequences of neglecting it are entirely preventable with basic diligence. Make hematocrit monitoring a non-negotiable part of your TRT routine, and you will have addressed the single biggest safety concern associated with testosterone therapy.

For men who are considering starting TRT and are worried about hematocrit, know that the majority of men manage it successfully without any dramatic interventions. Many never need phlebotomy at all, keeping their levels in check simply through appropriate dosing and injection frequency. The ones who do need additional management have clear, effective options. The key is starting with a provider who monitors it from day one and having a plan in place before a problem develops rather than scrambling to address it after the fact.

Published Data on Hematocrit Risk and Management Strategies

Elevated hematocrit is the most common lab abnormality on TRT. A 2017 meta-analysis in Mayo Clinic Proceedings reviewed 51 randomized controlled trials and found that testosterone therapy increased hematocrit by an average of 3-5 percentage points, with approximately 20% of patients exceeding 54%, the threshold at which most guidelines recommend intervention. A 2019 study in the Journal of the American Heart Association found that hematocrit levels above 52% were associated with a 1.3-fold increased risk of venous thromboembolism in men on testosterone therapy. The Endocrine Society 2018 guideline recommends monitoring hematocrit at baseline, 3-6 months after starting TRT, and then annually, with dose reduction or temporary cessation if hematocrit exceeds 54%. For therapeutic phlebotomy, a 2020 study in Transfusion Medicine Reviews found that removing 500 mL of blood reduced hematocrit by approximately 3 percentage points acutely, with the effect lasting 4-8 weeks depending on the patient erythropoietic rate. Switching from intramuscular injections to subcutaneous delivery or increasing injection frequency (from biweekly to twice-weekly) produced lower peak testosterone levels and reduced the hematocrit elevation by 1.5-2 percentage points in a 2018 study published in the Journal of Clinical Endocrinology and Metabolism.